NAFLD

DEADLINE ALERT for ADSK, CMP, AKRO, EXAI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Mercoledì, Maggio 8, 2024
FDA, Cirrhosis, Compass Minerals, Inflammation, NAFLD, Investment, EFX, Risk, Suite, Class, Steatosis, NASH, Law, Ethics, Patient, Defendant, Åkerö, Telephone, Knowledge

BENSALEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

AKRO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Akero Therapeutics, Inc.

Retrieved on: 
Martedì, Maggio 7, 2024
FDA, Efficacy, Cirrhosis, Inflammation, LLP, NAFLD, EFX, Liver disease, Viability, Fatty liver disease, Steatosis, NASH, Complaint, Patient, DSM-IV codes, SAN, Person, Pharmaceutical industry

Akero is a clinical stage biopharmaceutical company that was founded to develop transformational medicines for patients with serious metabolic diseases that lack effective treatment options.

Key Points: 
  • Akero is a clinical stage biopharmaceutical company that was founded to develop transformational medicines for patients with serious metabolic diseases that lack effective treatment options.
  • The Company is currently focused on advancing its lead product candidate efruxifermin (“EFX”) to provide a new treatment for patients with nonalcoholic steatohepatitis ("NASH"), a serious liver disease.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)

Retrieved on: 
Giovedì, Maggio 9, 2024
Class Action Lawsuit, Professional Services, Legal, FDA, Cirrhosis, Inflammation, NAFLD, EFX, News, Suite, Steatosis, NASH, Law, Patient, Defendant, Court, Åkerö, Telephone, Cryptocurrency

Investors suffering losses on their Akero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at (215) 638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Akero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at (215) 638-4847 or by email to [email protected] .
  • On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint.
  • On this news, Akero’s stock price fell $30.39, or 62.6%, to close at $18.15 per share on October 10, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors

Retrieved on: 
Martedì, Maggio 7, 2024
Class Action Lawsuit, Professional Services, Legal, FDA, Cirrhosis, Inflammation, NAFLD, EFX, News, Suite, GPM, Steatosis, NASH, Patient, Defendant, Court

Akero investors have until June 25, 2024 to file a lead plaintiff motion.

Key Points: 
  • Akero investors have until June 25, 2024 to file a lead plaintiff motion.
  • On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint.
  • On this news, Akero’s stock price fell $30.39, or 62.6%, to close at $18.15 per share on October 10, 2023, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors

Retrieved on: 
Lunedì, Maggio 6, 2024
Class Action Lawsuit, Professional Services, Legal, FDA, Cirrhosis, Inflammation, NAFLD, EFX, News, Suite, Steatosis, NASH, Law, Patient, Defendant, Åkerö, Telephone

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO ) common stock between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”).

Key Points: 
  • Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO ) common stock between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”).
  • Akero investors have until June 25, 2024 to file a lead plaintiff motion.
  • Investors suffering losses on their Akero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors

Retrieved on: 
Lunedì, Maggio 6, 2024
Legal, Professional Services, FDA, Cirrhosis, Inflammation, NAFLD, EFX, News, Suite, Steatosis, NASH, Law, Patient, Defendant, Court, Åkerö, Person

Akero investors have until June 25, 2024 to file a lead plaintiff motion.

Key Points: 
  • Akero investors have until June 25, 2024 to file a lead plaintiff motion.
  • On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint.
  • On this news, Akero’s stock price fell $30.39, or 62.6%, to close at $18.15 per share on October 10, 2023, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Merck Manuals: The Facts on Fatty Liver and its New Name

Retrieved on: 
Mercoledì, Maggio 8, 2024
Liver disease, Fatty liver disease, NAFLD, Blood, Blood pressure, MD, Human, Tholey, Thomas Jefferson University, Obesity, Light, Patient, Editorial, Cholesterol, AASLD, Metabolic syndrome, Insulin resistance, Dietary supplement

She also explains why doctors are moving away from the term fatty liver towards more detailed terminology.

Key Points: 
  • She also explains why doctors are moving away from the term fatty liver towards more detailed terminology.
  • In 2023, the American Association for the Study of Liver Disease (AASLD) updated the nomenclature around steatotic liver disease and fatty liver.
  • Fatty liver due to any condition except consumption of large amounts of alcohol was previously called nonalcoholic fatty liver disease (NAFLD).
  • Tholey stresses even social drinking can have a negative effect, and it's not just hard alcohol that can lead to fatty liver.

Akero Therapeutics, Inc. (AKRO) Investor Notice: Robbins LLP Reminds Stockholders of the Akero Therapeutics, Inc. Class Action

Retrieved on: 
Venerdì, Maggio 3, 2024
Class Action Lawsuit, Professional Services, Legal, FDA, Efficacy, Cirrhosis, Inflammation, LLP, NAFLD, EFX, Liver disease, Viability, Fatty liver disease, Steatosis, NASH, Complaint, Patient, DSM-IV codes, Person, Pharmaceutical industry

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Akero Therapeutics, Inc. (NASDAQ: AKRO) securities between September 13, 2022 and October 9, 2023.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Akero Therapeutics, Inc. (NASDAQ: AKRO) securities between September 13, 2022 and October 9, 2023.
  • Akero is a clinical stage biopharmaceutical company that was founded to develop transformational medicines for patients with serious metabolic diseases that lack effective treatment options.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Valbiotis publishes its annual accounts 2023

Retrieved on: 
Venerdì, Maggio 3, 2024
FDA, Sales management, Partnership, Hypercholesterolemia, Sleep, INSIGHT, Prevalence, Insulin resistance, Inflammation, DSM-IV codes, Food, Communication, Cholecalciferol, Executive Committee, Pharmacist, Pharmacy, Volunteering, INAF, Phase, Practitioner, Incretin, EFSA, Safety, Omega-3 fatty acid, Agonal respiration, Human, LDL, Marketing, Prediabetes, NAFLD, Endocrine gland, NDI, Food and Drug Administration, Meal, Commercial, Dietary supplement, Blood pressure, Patient, Statutory auditor, Metabolism, Hypertension, Cardiovascular disease, Bank statement, Pharmaceutical industry

Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.

Key Points: 
  • Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.
  • By accelerating its structuring, Valbiotis also laid the foundations for 2024, which promises to be particularly fruitful.
  • The Company's 2023 financial statements, drawn up in accordance with IFRS, were approved by the Board of Directors on April 23, 2024.
  • They have been audited by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com/en (investors section).

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

Retrieved on: 
Giovedì, Maggio 2, 2024
Infection, MASH, Liver disease, Cirrhosis, NAFLD, American Gastroenterological Association, NIH, Publication, Research, Cell Metabolism, Yale University, American Liver Foundation, KOL, Journal of Clinical Pathology, Journal, NASH, Virginia Commonwealth University, Liver, Patient, Fibrosis, AASLD, Internal medicine, Medical Center, Division, SAN, VCU, Pharmaceutical industry

The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH.

Key Points: 
  • The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH.
  • A replay of the webinar will be accessible in the investors section of 89bio’s website following the event.
  • He has also served as Secretary as well as President of the American Association for the Study of Liver Diseases.
  • He has been continuously funded by the NIH since 1995 and is the principal investigator of four active NIH grants.